Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 85 articles: HTML format

Single Articles

September 2025
1. SEEWALDT VL, Schedin PJ
   Breastfeeding after breast cancer: a need for further mechanistic study.
   J Natl Cancer Inst. 2025 Sep 18:djaf240. doi: 10.1093.
   PubMed    
   
   
   
2. IRAJIZAD E, Hanash S
   Breast cancer risk assessment: current challenges and the emerging role of blood-based protein biomarkers.
   J Natl Cancer Inst. 2025 Sep 3:djaf215. doi: 10.1093.
   PubMed    
   
   
   
3. PRESTI D, Di Meglio A, Havas J, Pagliuca M, et al
   Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.
   J Natl Cancer Inst. 2025 Sep 3:djaf256. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. SAHIN TK, Guven DC, Aksoy S
   RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
   J Natl Cancer Inst. 2025 Sep 3:djaf254. doi: 10.1093.
   PubMed    
   
   
   August 2025
5. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
   Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
   J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. TARANTINO P, Lee D, Foldi J, Soulos PR, et al
   Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
   J Natl Cancer Inst. 2025 Aug 14:djaf220. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. LAMBERTINI M, Allegranza D, Laubender RP, Harbeck N, et al
   Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
   J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. MO T, Partridge A, Joffe M, Cubasch H, et al
   Survival deficits in young women with breast cancer in Sub-Saharan africa: the ABC-DO cohort.
   J Natl Cancer Inst. 2025 Aug 7:djaf213. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. WEI Y, Castro E, Yin K, Zhang M, et al
   Ambient air pollution and mortality in older breast cancer patients.
   J Natl Cancer Inst. 2025 Aug 5:djaf217. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. SPOOR J, Mureau MAM, Tissier RLM, Hommes J, et al
    Breast implant illness after reconstruction with silicone breast implants.
    J Natl Cancer Inst. 2025;117:1717-1728.
    PubMed     Abstract available
    
    
    
11. YU TT, Hoyt AC, Joines MM, Fischer CP, et al
    Mammographic classification of interval breast cancers and artificial intelligence performance.
    J Natl Cancer Inst. 2025;117:1627-1638.
    PubMed     Abstract available
    
    
    July 2025
12. ZHU T, Bu J, Zhu X
    RE: Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2025 Jul 23:djaf187. doi: 10.1093.
    PubMed    
    
    
    
13. WATT GP, Reiner AS, Shu X, Malone KE, et al
    Polygenic risk of coronary artery disease for long-term survivors of breast cancer.
    J Natl Cancer Inst. 2025 Jul 16:djaf189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. BOTTERI E, Hjorth S, Conforti F, Bagnardi V, et al
    Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Jul 14:djaf178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. SYLEOUNI ME, Joshu CE, Coresh J, Gunter MJ, et al
    Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC.
    J Natl Cancer Inst. 2025 Jul 7:djaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. BLONDEAUX E, Delucchi V, Mariamidze E, Bernstein-Molho R, et al
    Breastfeeding after breast cancer in young BRCA carriers.
    J Natl Cancer Inst. 2025 Jul 7:djaf177. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. STECKLEIN SR, Martin M, Villacampa G, Del Monte-Millan M, et al
    Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
    J Natl Cancer Inst. 2025 Jul 2:djaf162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    PubMed     Abstract available
    
    
    June 2025
19. ARECCO L, Blondeaux E, Bruzzone M, Arpino G, et al
    Prognostic implications of risk definitions from the monarchE and NATALEE trials.
    J Natl Cancer Inst. 2025;117:1198-1208.
    PubMed     Abstract available
    
    
    May 2025
20. ABUBAKAR M, Duggan MA, Fan S, Pfeiffer RM, et al
    Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes.
    J Natl Cancer Inst. 2025 May 14:djaf070. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. LI D, Liu Y, Duan Q, Chen X, et al
    RE: Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2025 May 7:djaf115. doi: 10.1093.
    PubMed    
    
    
    
22. TUESLEY KM, Spilsbury K, Pearson SA, Donovan P, et al
    Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
    J Natl Cancer Inst. 2025;117:1046-1055.
    PubMed     Abstract available
    
    
    
23. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available
    
    
    
24. BUQUE A, Bloy N, Petroni G, Jimenez-Cortegana C, et al
    Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.
    J Natl Cancer Inst. 2025;117:934-947.
    PubMed     Abstract available
    
    
    April 2025
25. ZHANG J, Zhang L, Liu Z, Jia Y, et al
    RE: Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Apr 9:djaf093. doi: 10.1093.
    PubMed    
    
    
    
26. LOPEZ-FERNANDEZ A, Duran-Lozano L, Villacampa G, Pardo M, et al
    A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.
    J Natl Cancer Inst. 2025 Apr 1:djaf067. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. BARGON CA, Mink van der Molen DR, Young-Afat DA, Batenburg MCT, et al
    Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery-a longitudinal, multicenter cohort study.
    J Natl Cancer Inst. 2025;117:781-789.
    PubMed     Abstract available
    
    
    
28. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
    Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:728-736.
    PubMed     Abstract available
    
    
    
29. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
    High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:719-727.
    PubMed     Abstract available
    
    
    
30. HAMMARSTROM M, Gabrielson M, Bergqvist J, Lundholm C, et al
    Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.
    J Natl Cancer Inst. 2025;117:629-636.
    PubMed     Abstract available
    
    
    March 2025
31. KURIAN AW, Furgal AKC, Radhakrishnan A, Veenstra CM, et al
    Extended endocrine therapy use and decision making after breast cancer diagnosis.
    J Natl Cancer Inst. 2025 Mar 31:djaf076. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. SAMMONS SL, Sanglier T, Leone JP, Erick TK, et al
    Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients.
    J Natl Cancer Inst. 2025 Mar 31:djaf048. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. LYNCE F, Niman SM, Kai M, Ma SR, et al
    Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score.
    J Natl Cancer Inst. 2025 Mar 31:djaf088. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. BETTARIGA F, Taaffe DR, Borsati A, Avancini A, et al
    Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2025 Mar 20:djaf062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. HUANG Y, Kwan ML, Heckbert SR, Smith NL, et al
    Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Mar 11:djaf063. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
36. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    January 2025
37. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    PubMed     Abstract available
    
    
    
38. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available
    
    
    
39. GANZ PA, Cecchini RS, White JR, Vicini FA, et al
    Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
    J Natl Cancer Inst. 2025;117:103-111.
    PubMed     Abstract available
    
    
    December 2024
40. ZHANG Y, Lv P
    RE: Genetic risk, health-associated lifestyle, and risk of early-onset total cancer and breast cancer.
    J Natl Cancer Inst. 2024 Dec 19:djae322. doi: 10.1093.
    PubMed    
    
    
    
41. LOLAS-HAMAMEH S, Lieberman S, Sarahneh A, Walsh T, et al
    TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers.
    J Natl Cancer Inst. 2024 Dec 14:djae334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. PETITJEAN C, Wilcox N, Ficorella L, Dennis J, et al
    Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
    J Natl Cancer Inst. 2024 Dec 12:djae335. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ABDOU Y, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
    J Natl Cancer Inst. 2024 Dec 5:djae314. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. PALMER S, Valachis A, Lindman H, Smith DR, et al
    Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.
    J Natl Cancer Inst. 2024 Dec 4:djae315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. JOHANSSON A, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2024 Dec 4:djae268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. SERRANO D, Johansson H, Bertelsen BE, Gandini S, et al
    Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules.
    J Natl Cancer Inst. 2024;116:1979-1982.
    PubMed     Abstract available
    
    
    
47. ARTESE AL, Zhou X, Tometich DB, Small BJ, et al
    Physical activity and cognition: longitudinal findings from the Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2024;116:2009-2021.
    PubMed     Abstract available
    
    
    
48. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    J Natl Cancer Inst. 2024;116:1904-1913.
    PubMed     Abstract available
    
    
    November 2024
49. GRAFF SL, Tinianov S, Kalinsky K
    "Nailing down" risk and improving outcomes in early-stage breast cancer.
    J Natl Cancer Inst. 2024 Nov 22:djae278. doi: 10.1093.
    PubMed    
    
    
    
50. ROMANOS-NANCLARES A, Willett WC, Rosner B, Stover DG, et al
    Proinflammatory Dietary Pattern and Risk of Total and Subtypes of Breast Cancer Among U.S. Women.
    J Natl Cancer Inst. 2024 Nov 20:djae301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. ABOUMRAD M, Joshu C, Visvanathan K
    Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study.
    J Natl Cancer Inst. 2024 Nov 12:djae287. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. ROBERTI S, van Leeuwen FE, Diallo I, de Vathaire F, et al
    Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.
    J Natl Cancer Inst. 2024 Nov 1:djae274. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
53. FOSTER VM, Trentham-Dietz A, Stout NK, Lee CI, et al
    Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts.
    J Natl Cancer Inst. 2024 Oct 30:djae272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. KJAERGAARD KA, Kousholt A, Thomsen RW, Woolpert KM, et al
    Risk of type-2-diabetes after breast cancer treatment: a population-based cohort study in Denmark.
    J Natl Cancer Inst. 2024 Oct 22:djae261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. KARLSSON P, Fyles A, Chang SL, Arrick B, et al
    Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2024 Oct 18:djae262. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. ROMANOS-NANCLARES A, Schernhammer E, Willett WC, Holmes MD, et al
    Consumption of aspartame and risk of breast cancer in the Nurses' Health Studies.
    J Natl Cancer Inst. 2024 Oct 17:djae259. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. SHERMAN ME, Winham SJ, Vierkant RA, Mccauley BM, et al
    Polygenic risk scores stratify breast cancer risk among women with benign breast disease.
    J Natl Cancer Inst. 2024 Oct 16:djae255. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. JOHN EM, Koo J, Ingles SA, Keegan TH, et al
    Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.
    J Natl Cancer Inst. 2024 Oct 11:djae254. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. WATTS EL, Moore SC, Abar L, Hong HG, et al
    Physical activity, metabolites, and breast cancer associations.
    J Natl Cancer Inst. 2024 Oct 9:djae246. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. CARROLL JE, Crespi CM, Cole S, Ganz PA, et al
    Transcriptomic markers of biological aging in breast cancer survivors: a longitudinal study.
    J Natl Cancer Inst. 2024 Oct 8:djae201. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
61. MARCZYK M, Kahn A, Silber A, Rosenblit M, et al
    Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
    J Natl Cancer Inst. 2024 Sep 30:djae241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. PAGLIUCA M, Havas J, Thomas E, Drouet Y, et al
    Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
    J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. DAS S, Wentzensen N, Sawaya GF, Egemen D, et al
    Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.
    J Natl Cancer Inst. 2024;116:1525-1529.
    PubMed     Abstract available
    
    
    
64. MANDELBLATT J, Dage JL, Zhou X, Small BJ, et al
    Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.
    J Natl Cancer Inst. 2024;116:1495-1507.
    PubMed     Abstract available
    
    
    August 2024
65. ZHANG Y, Lindstrom S, Kraft P, Liu Y, et al
    Genetic Risk, Health-Associated Lifestyle, and Risk of Early-onset Total Cancer and Breast Cancer.
    J Natl Cancer Inst. 2024 Aug 27:djae208. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. EBRAHIMOGHLI R, Aghaei MH, Azami-Aghdash S, Houssami N, et al
    Uptake of Breast Cancer Screening Practices in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2024 Aug 12:djae187. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. FOLDI J, Carleton N, Anderson SJ, Rastogi P, et al
    Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials.
    J Natl Cancer Inst. 2024 Aug 10:djae188. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. MALAGON T
    Time to change the paradigm for primary endpoints in cancer screening trials?
    J Natl Cancer Inst. 2024;116:1187-1189.
    PubMed    
    
    
    July 2024
69. MASSA D, Vernieri C, Nicole L, Criscitiello C, et al
    Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
    J Natl Cancer Inst. 2024 Jul 31:djae178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. HURSON AN, Ahearn TU, Koka H, Jenkins BD, et al
    Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.
    J Natl Cancer Inst. 2024 Jul 17:djae172. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
72. DENT R, Cortes J, Pusztai L, McArthur H, et al
    Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
    J Natl Cancer Inst. 2024 Jun 24:djae129. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. JAGUST P, Powell AM, Ola M, Watson L, et al
    RET overexpression leads to increased brain metastatic competency in luminal breast cancer.
    J Natl Cancer Inst. 2024 Jun 10:djae091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. CHUA AV JR, Sheng H, Liang E, Gandhi S, et al
    Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
    J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. LIN J, Ouyang Y, Li Y, Jin L, et al
    Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
    J Natl Cancer Inst. 2024 Jun 4:djae115. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
76. 
    Correction to: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy.
    J Natl Cancer Inst. 2024 May 8:djae093. doi: 10.1093.
    PubMed    
    
    
    
77. VO JB, Ramin C, Veiga LHS, Brandt C, et al
    Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
    J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
78. OMOLEYE OJ, Esserman LJ, Olopade OI
    RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    J Natl Cancer Inst. 2024;116:627-628.
    PubMed    
    
    
    
79. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
    Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
    J Natl Cancer Inst. 2024;116:580-587.
    PubMed     Abstract available
    
    
    
80. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
    TP53-associated early breast cancer: new observations from a large cohort.
    J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
81. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
    J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
    Predicting five-year interval second breast cancer risk in women with prior breast cancer.
    J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. LEE CI, Elmore JG
    Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
    J Natl Cancer Inst. 2024;116:343-344.
    PubMed    
    
    
    
84. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
    The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
    J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
85. LI JL, McClellan JC, Zhang H, Gao G, et al
    Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
    J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.